Ewing's Sarcoma (Primitive Neuroectodermal Tumor) of Seminal Vesicles: A Case Report

Abstract

Malignant tumors of the seminal vesicles are rare; they may be of epithelial or mesenchymal origin. Carcinomas are the most common and pelvic sarcoma may be confused with a primary tumor of the seminal vesicles. Little is known of the prognosis and best sequence of treatment in such sarcoma. We report a rare case of extra-skeletal Ewing sarcoma/primitive neuroectodermal tumor of the seminal vesicles in a 54-yearold man who presented with chronic lower abdominal pain, urinary retention, and severe constipation. Pelvic CT scan and MRI confirmed the presence of a soft tissue mass lesion centered on seminal vesicles. A trans-gluteal Tru-cut biopsy confirmed the diagnosis. Three cycles of the preoperative chemotherapy VAC/IE (vincristine, Adriamycin and cyclophosphamide, followed by ifosfamide and etoposide) protocol achieved an excellent clinical response.

Cardiotoxicity in Cancer Patients: The Prevalence, Risk Factors, and Cardioprotective Measures in a Cancer Centre in Saudi Arabia

“…In this study, the prevalence of cardiotoxicity was 12.5%. The result was similar to our previous report of 12% cardiotoxicity occurrence among cancer patients during anticancer treatment in Najran City [ 4 ]. Prior studies have shown variable prevalences of cardiotoxicity.…”

“…The anticancer therapy agent was grouped into monoclonal agents, alkylating agents, anthracyclines agents, and taxans. The cardiac protection agents were grouped into beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, statins, and antiplatelets [ 4 ].…”

“…A recent survey in Najran, Saudi Arabia, on the prevalence of cardiotoxicity among 78 patients receiving anticancer therapy reported alarming figures of 12% of cardiotoxicity occurrence [ 4 ]. Additionally, dyslipidemia, previous heart, and impaired baseline ejection fraction (EF) were associated with an increased risk of cardiotoxicity.…”

“…Furthermore, statin and antiplatelet agents were protective agents against cardiotoxicity. Previous research has found a conflicting relationship between anticancer treatment and drug-related cardiotoxicity, whether in single or combination regimens [ 4 - 6 ]. Most studies used relative risks (RRs) or odds ratios (ORs) to assess anticancer-induced cardiotoxicity.…”

“…Most studies used relative risks (RRs) or odds ratios (ORs) to assess anticancer-induced cardiotoxicity. However, these investigations failed to account for the interval between the start of anticancer therapy and the onset of cardiotoxicity during the treatment period, which may have influenced the consistency of their results [ 4 , 6 ]. Additionally, the incidence of cardiotoxicity and adherence to monitoring recommendations remains poorly understood in Saudi Arabia.…”